Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not produce enough of the hormone testosterone. Axiron is a highly profitable testosterone replacement therapy, with a patent expiration of February 19, 2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.
Coined “The Wittert Study”, after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now hovers at 471 billion dollars
Description: Andriol first became available in the early 1980′s. This compound contains 40 mg of testosterone undecanoate, based in oil (oleic acid) and sealed inside a capsule. Subtracting the ester weight, this equates to a dosage of approximately 25mg of raw ...
Description: Usage: Pharmaceutical material, Steroid hormone, Anabolin. Male hormone drugs for male sexual dysfunction, aplastic anemia. Testosterone propionate is also called the testosterone propionate, testosterone propionate, under normal temperature for whit...